Source-grounded facts extracted from ATOSSA THERAPEUTICS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ATOSSA THERAPEUTICS, INC. entered into Purchase Agreement with institutional investors valued at approximately $4.1 million (effective 2026-06-10).
“On June 10, 2026, Atossa Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors”
ATOSSA THERAPEUTICS, INC. shareholders approved Advisory Vote on Executive Compensation at the 2026-05-07 meeting.
“The stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 1,530,390 444,616 39,793 2,222,160”
ATOSSA THERAPEUTICS, INC. shareholders approved Approval of Amendment to the Amended and Restated Certificate of Incorporation to Effect a Reverse Stock Split of the Common Stock, if Deemed Necessary or Appropriate by the Board at the 2026-05-07 meeting.
“The stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio from 2:1 to 20:1, inclusive, if determined necessary or appropriate by the Board, by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 2,336,815 1,866,873 33,271 0”
ATOSSA THERAPEUTICS, INC. shareholders approved Ratification of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-07 meeting.
“The stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 3,714,889 370,496 151,574 0”
ATOSSA THERAPEUTICS, INC. shareholders approved Election of three Class II directors at the 2026-05-07 meeting.
“The stockholders elected the three Class II directors by the following votes: Nominee Votes For Votes Withheld Broker Non-Votes • Stephen J. Galli, M.D. 1,726,410 288,389 2,222,160 • Richard I. Steinhart 1,730,171 284,628 2,222,160 • Tessa Cigler, M.D., M.P.H. 1,750,694 264,105 2,222,160”
ATOSSA THERAPEUTICS, INC. reported financial results for the first quarter ended March 31, 2026.
“On May 8, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the first quarter ended March 31, 2026 financial results and providing a Company update.”
ATOSSA THERAPEUTICS, INC. reported financial results for the fourth quarter and year ended December 31, 2025.
“On March 25, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the fourth quarter and year ended December 31, 2025 financial results and providing a Company update.”
ATOSSA THERAPEUTICS, INC. terminated Prior Agreement with Jefferies LLC (effective 2026-02-19).
“On February 19, 2026, the Company delivered written notice to Jefferies LLC indicating that it is terminating the Open Market Sale Agreement SM (the “Prior Agreement”) by and between the Company and Jefferies LLC, dated November 19, 2024, effective as of February 19, 2026.”
ATOSSA THERAPEUTICS, INC. entered into Sales Agreement with Rodman & Renshaw LLC valued at up to $50,000,000 (effective 2026-02-20).
“On February 20, 2026, Atossa Therapeutics, Inc. (the “Company”) entered into the At the Market Offering Agreement, dated February 20, 2026 (the “Sales Agreement”), with Rodman & Renshaw LLC (the “Sales Agent”), pursuant to which the Company may offer and sell from time to time up to $50,000,000 of shares of the Company’s common stock”
ATOSSA THERAPEUTICS, INC. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).
“February 17, 2026, Atossa Therapeutics, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it had regained compliance with the minimum closing bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. As previously disclosed, on February 21, 2025, the Company was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Co”
ATOSSA THERAPEUTICS, INC.: Approved a 15:1 reverse stock split of common stock and filed an amendment to the Amended and Restated Certificate of Incorporation with the Delaware Secretary of State, effective February 2, 2026 (effective 2026-02-02).
“the Company filed an amendment to its Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), with the Secretary of State of the State of Delaware (the “Amendment”).”
ATOSSA THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“February 21, 2025, Atossa Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it was not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq, because the Company's common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Company’s initial compliance period ended on August 20, 2025, and the Company subsequently requested an extension. On August 21, 2025, the Company was inf”
ATOSSA THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“February 21, 2025, Atossa Therapeutics, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq, because the Company's common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Company has until August 20, 2025 to regain compliance with Nasdaq Listing Rule 5550(a)(2). In the event the Company does not regain compliance by then, the Company may b”
Heather Rees was appointed as Chief Financial Officer at ATOSSA THERAPEUTICS, INC..
“On June 27, 2024, the Board of Directors (the “Board”) of the Company appointed Heather Rees, previously the Company’s Senior Vice President, Finance and Accounting, to serve as Chief Financial Officer and to continue serving as principal financial and accounting officer, effective immediately.”
ATOSSA THERAPEUTICS, INC. reported financial results for fiscal quarter ended March 31, 2024.
“On May 13, 2024, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the quarter ended March 31, 2024 financial results and providing a Company update.”
ATOSSA THERAPEUTICS, INC. reported financial results for the fourth quarter and full year ended December 31, 2023.
“Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced financial results for the fourth quarter and full year ended December 31, 2023”
ATOSSA THERAPEUTICS, INC. reported financial results for the year ended December 31, 2023.
“Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced financial results for the forth quarter and full year ended December 31, 2023, and provided an update on recent Company developments.”
ATOSSA THERAPEUTICS, INC. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).
“March 15, 2024, Atossa Therapeutics, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it had regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. As previously disclosed, on September 26, 2023, the Company was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Company was”
Tessa Cigler was appointed as Class II Director at ATOSSA THERAPEUTICS, INC..
“On March 9, 2024, the Board of Directors (the “Board”) of Atossa Therapeutics, Inc. (the “Company”) expanded its size and appointed Dr. Tessa Cigler, M.D., M.P.H. as a Class II director to hold office until the 2026 Annual Meeting of Stockholders and until her successor shall have been duly elected and qualified, effective immediately.”
ATOSSA THERAPEUTICS, INC. reported financial results for the quarter ended September 30, 2023.
“On November 13, 2023, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the quarter ended September 30, 2023 financial results and a Company update.”
Greg Weaver departed as Class I Director at ATOSSA THERAPEUTICS, INC..
“Mr. Finn succeeded Greg Weaver as a Class I director”
Jonathan Finn was appointed as Class I Director at ATOSSA THERAPEUTICS, INC..
“Jonathan Finn, CFA, has been appointed to the Company's board of directors, effective immediately.”
Heather Rees was appointed as principal financial and accounting officer at ATOSSA THERAPEUTICS, INC..
“In connection with Mr. Weaver’s resignation, the Company has appointed Heather Rees, age 51, as the Company’s principal financial and accounting officer.”
Greg Weaver resigned as member of the Board of Directors at ATOSSA THERAPEUTICS, INC..
“Mr. Weaver’s termination of service as an employee served as his resignation from all other positions with the Company, including as a member of the Board of Directors.”
Greg Weaver resigned as Executive Vice President and Chief Financial Officer at ATOSSA THERAPEUTICS, INC..
“Mr. Weaver tendered his resignation to pursue other opportunities and not due to any disagreement with the Company.”
ATOSSA THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“September 26, 2023, Atossa Therapeutics, Inc. (“the Company”) received a letter from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) – bid price, because the Company's common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Company has until March 25, 2024 to regain compliance. The letter also states that the Nasdaq staff will provide written notification that the Company has regained compliance if the bid price of the Company's common stock close”
ATOSSA THERAPEUTICS, INC. reported the quarter ended June 30, 2023 results: net income Net loss for the second quarter of 2023 was $9,830.
“On August 14, 2023, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the quarter ended June 30, 2023 financial results and a Company update.”
ATOSSA THERAPEUTICS, INC. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).
“July 13, 2023, Atossa Therapeutics, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it had regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. As previously disclosed, on October 5, 2022, the Company was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Company was init”
ATOSSA THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding board independence (rules 5605(b)(1)).
“June 21, 2023, Atossa Therapeutics, Inc. (the “Company”) received formal notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company no longer complies with Nasdaq Listing Rule 5605(b)(1), which requires a board of directors comprised of a majority of independent directors (the “Rule”), due to the appointment of Greg Weaver, formerly an independent director, as the Company’s Executive Vice President and Chief Financial Officer. The Staff’s notice has no immediate effect on the listing of the Company’s common stock, which the”
Kyle Guse departed as General Counsel and Chief Financial Officer at ATOSSA THERAPEUTICS, INC..
“Mr. Weaver succeeds Kyle Guse, who ceased to serve as the Company’s General Counsel and Chief Financial Officer as of May 26, 2023.”
Greg Weaver was appointed as Executive Vice President and Chief Financial Officer at ATOSSA THERAPEUTICS, INC..
“Effective as of June 1, 2023 (the “Effective Date”), Atossa Therapeutics, Inc. (the “Company”) appointed Greg Weaver as the Company’s Executive Vice President and Chief Financial Officer.”
ATOSSA THERAPEUTICS, INC. engaged Ernst & Young LLP as its auditor.
“The Audit Committee, on and effective as of the Effective Date, appointed Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
ATOSSA THERAPEUTICS, INC. dismissed BDO USA LLP as its auditor.
“On May 17, 2023 (the “ Effective Date ”), the Audit Committee dismissed BDO USA LLP (“ BDO ”) as the Company’s independent registered public accounting firm, effective as of that date.”
ATOSSA THERAPEUTICS, INC. reported financial results for fiscal quarter ended March 31, 2023.
“Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focus on breast cancer, today announces financial results for the fiscal quarter ended March 31, 2023, and provides an update on recent company developments.”
ATOSSA THERAPEUTICS, INC. shareholders approved Advisory vote to approve executive compensation at the 2023-05-04 meeting.
“The stockholders approved an advisory non-binding vote on executive compensation as follows: Votes For Votes Against Abstain Broker Non-Votes 21,091,953 4,707,752 910,013 30,090,622”
ATOSSA THERAPEUTICS, INC. shareholders approved Ratification of the selection of BDO USA LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-04 meeting.
“The stockholders ratified the appointment of BDO USA LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 as set forth below: Votes For Votes Against Abstain Broker Non-Votes 54,079,294 1,607,433 1,113,613 0”
ATOSSA THERAPEUTICS, INC. shareholders approved Election of two Class II Directors at the 2023-05-04 meeting.
“The stockholders elected two Class II directors as set forth below: Nominee Votes For Votes Withheld Broker Non-Votes Stephen J. Galli, M.D. 15,993,221 10,716,498 30,090,621 Richard I. Steinhart 22,292,391 4,417,328 30,090,621”
ATOSSA THERAPEUTICS, INC.: Modified the quorum requirement for stockholder meetings from a majority to at least one-third of outstanding shares (effective 2023-04-26).
“On April 26, 2023, the Board of Directors of Atossa Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated Bylaws (the “Bylaws”), effective immediately. The amendment modified the provisions for determining the presence of a quorum at all meetings of stockholders to provide that the presence, in person or by proxy, of the holders of at least one-third of all issued and outstanding shares of common stock entitled to vote at the meeting will constitute a quorum at all meetings of the stockholders for the transaction of business.”
ATOSSA THERAPEUTICS, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“April 4, 2023, the Company was informed that the deadline for compliance was extended by 180 days, or until October 2, 2023. The October 5, 2022 NASDAQ notice of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on the NASDAQ Stock Market. The Company intends to actively monitor the bid price for its common stock between now and October 2, 2023, and will consider available options to resolve the deficiency and regain compliance with the minimum bid price requirement, including, if necessary, effectuating a reverse stock split. . * * * SIGNATURES Purs”
ATOSSA THERAPEUTICS, INC. reported financial results for the fiscal year ended December 31, 2022.
“On March 22, 2023, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the year ended December 31, 2022 financial results and a Company update.”
ATOSSA THERAPEUTICS, INC. reported the fiscal quarter ended September 30, 2022 results: revenue no source of revenue.
“Atossa Therapeutics, Inc. (Nasdaq: ATOS), today announces financial results for the fiscal quarter ended September 30, 2022”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.